Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Baqsimi ® (glukagon näspulver)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
People with a history of phaeochromocytoma were excluded from the NG clinical studies.1
NG is contraindicated in people with phaeochromocytoma because glucagon may stimulate release of catecholamines from the tumor.2
If the person develops a dramatic increase in BP, use of non-selective α-adrenergic blockade has been shown to be effective in lowering BP.2
Tumor-Induced Release of Catecholamines
Phaeochromocytomas are a rare neuroendocrine tumor usually in the adrenal medulla3,4and less frequently occur in the form of extra-adrenal paragangliomas.3 Phaeochromocytoma tumor cells have specific glucagon-binding receptors, which are stimulated in response to glucagon administration and can cause the release of high levels of circulating catecholamines norepinephrine and epinephrine.3,4
Clinical presentation varies considerably in people due to the hemodynamic and metabolic actions of the catecholamines (Table 1).3
Table 1. Signs and Symptoms of a Phaeochromocytoma3
Signs |
Symptoms |
Hypertensiona |
Headache |
Tachydardia or reflex bradycardia |
Excessive sweating |
Postural hypotension |
Palpitations |
Pallor |
Anxiety |
Flushing |
Tremors |
Fasting hyperglycemia |
Pain in chest or abdomen |
Increased respiratory rate |
Fatigue or weakness |
Weight loss |
Nausea or vomiting |
Decreased GI motility |
Dizziness |
Psychosis |
Paresthesias |
|
Visual disturbances |
Constipationb |
|
Abbreviation: GI = gastrointestinal.
a Sustained or paroxysmal.
Injectable Glucagon
Phaeochromocytomas have caused multiorgan failure and rare, life-threatening hypertensive crises as a result of very high levels of catecholamines being released in response to injectable glucagon administration.3,4
At one time, injectable glucagon was used to confirm the diagnosis of phaeochromocytoma. This is no longer recommended due to the risk of causing a phaeochromocytoma crisis.3,4
1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
3. Eisenhofer G, Rivers G, Rosas AL, et al. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Safety. 2007;30(11)1031-1062. https://doi.org/10.2165/00002018-200730110-00004
4. Hosseinnezhad A, Black R, Aeddula N, et al. Glucagon-induced pheochromocytoma crisis. Endocr Pract. 2011;17(3):e51-e54. https://doi.org/10.4158/EP10388.CR
Glossary
BP = blood pressure
IV = intravenous
NG = nasal glucagon (glucagon nasal powder)
Datum fӧr senaste ӧversyn 2019 M08 30